



VERIFICATION OF A TRANSLATION

I, the below named translator, hereby declare that:

My name and post office address are as stated below ;

That I am knowledgeable in the English language and in the Japanese language, and that I believe the English translation of the annexed document is a true and complete translation of Japanese Patent Application No. 2001-201356.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: November 16, 2004

Full name of the translator: Toshio Miyake

Signature of the translator: Toshio Miyake

Post Office Address: Bohsei Bldg., 3-20-12, Shin-Yokohama
Kohoku-ku, Yokohama, Kanagawa, Japan

BEST AVAILABLE COPY

Certificate (translation)

JAPAN PATENT OFFICE

This is to certify that the annexed is a true copy
of the following application as filed with this office.

Date of Application: July 2, 2001

Application Number: Patent Application No. 2001-201356

Applicant: RIKEN

Date: January 23, 2004

Commissioner,
Japan Patent Office

(signature) (seal)

Certificate No. 2003-3101953

[Name of Document] Application for Patent
 [Date of Submission] Year / Month / Day
 Heisei 13/ July / 2
 (2001)
 [Reference Number] RJH13-021T
 [Addressed to] Commissioner, Patent Office
 [IPC] C12P 19/02
 C12P 19/34
 C12N 15/09
 [Inventor]
 [Address] c/o RIKEN Yokohama Institute,
 7-22, Suehiro-cho 1-chome, Tsurumi-ku, Yokohama-shi,
 Kanagawa
 [Name] Yoko MOTODA
 [Inventor]
 [Address] c/o RIKEN Yokohama Institute,
 7-22, Suehiro-cho 1-chome, Tsurumi-ku, Yokohama-shi,
 Kanagawa
 [Name] Takashi YABUKI
 [Inventor]
 [Address] c/o RIKEN Yokohama Institute,
 7-22, Suehiro-cho 1-chome, Tsurumi-ku, Yokohama-shi,
 Kanagawa
 [Name] Takanori KIGAWA
 [Inventor]
 [Address] c/o RIKEN Yokohama Institute,
 7-22, Suehiro-cho 1-chome, Tsurumi-ku, Yokohama-shi,
 Kanagawa
 [Name] Shigeyuki YOKOYAMA
 [Applicant]
 [Identification Number] 000006792
 [Name] RIKEN
 [Representative]
 [Identification Number] 100080816
 [Patent Attorney]
 [Name] Asamichi KATO

[Official Fee]

[Registration Number] 030362

[Amount of Payment] 21,000 yen

[List of Documents]

[Name of Document]	Description	1
--------------------	-------------	---

[Name of Document]	Drawings	1
--------------------	----------	---

[Name of Document]	Abstract	1
--------------------	----------	---

[Name of the document] Description
[Title of the invention] METHOD OF PRODUCING TEMPLATE
DNA AND METHOD OF PRODUCING PROTEIN IN CELL-FREE PROTEIN
SYNTHESIS SYSTEM USING THE SAME

5

[Claims]

[Claim 1]

A method of producing a template DNA used for protein
synthesis comprising a step of

10 amplifying a linear double-stranded DNA by polymerase
chain reaction (PCR), contacting,

 a first double-stranded DNA fragment comprising
a sequence coding for a protein or a portion thereof,

 a second double-stranded DNA fragment comprising
15 a sequence overlapping with the 5' terminal region of
the first DNA fragment,

 a third double-stranded DNA fragment comprising
a sequence overlapping with the 3' terminal region of
the first DNA fragment,

20 a sense primer which anneals with the 5' terminal
region of the second DNA fragment, and

 an anti-sense primer which anneals with the 3'
terminal region of the third DNA fragment,

 wherein the second DNA fragment comprises a regulatory
25 sequence for transcription and translation of a gene, and the
concentrations of the second DNA fragment and the third DNA
fragment in the PCR solution each range from 5 to 2,500 pmol/L.

[Claim 2]

The method of claim 1, performing the PCR of claim 1 (the

second PCR) after amplifying a DNA by performing a PCR (a first PCR) to prepare the first DNA fragment, using the first PCR solution as the first DNA fragment, wherein the respective concentrations of primers remaining in the first PCR solution and primer dimers produced in the first PCR are less than 20 nmol/L in the second PCR solution.

[Claim 3]

The method of claim 2, wherein the respective concentrations of primers used for the first PCR are from 20 to 500 nmol/L.

[Claim 4]

The method of claim 2, wherein the second PCR is performed with the first PCR products which are diluted to 10- to 100-fold (at a final concentration in the second PCR solution).

[Claim 5]

The method of claim 2, further comprising a step of removing the primers and the primer dimers from the first PCR products.

[Claim 6]

The method of claim 2, wherein the template DNA of the first PCR is a recombinant microorganism or a culture broth thereof.

[Claim 7]

The method of any one of claims 1 to 6, wherein the second DNA fragment and/or the third DNA fragment is (are) single-stranded DNA(s) instead of double-stranded DNAs.

[Claim 8]

The method of any one of claims 1 to 7, wherein the sense primer and the anti-sense primer have the same nucleotide

sequence.

[Claim 9]

The method of any one of claims 1 to 8, wherein the third DNA fragment comprises a transcription termination sequence.

5 [Claim 10]

The method of any one of claims 1 to 9, wherein at least one of the second DNA fragment and the third DNA fragment comprises a sequence coding for a tag peptide, and the tag peptide is synthesized by being fused with the protein or a portion thereof.

10

[Claim 11]

The method of claim 10, wherein the tag peptide is maltose binding protein, cellulose binding domain, glutathione-S-transferase, thioredoxin, streptavidin binding peptide or histidine tag peptide.

15

[Claim 12]

The method of claim 10, wherein the tag peptide is a histidine tag peptide consisting of the amino acid sequence of SEQ ID No. 1.

20 [Claim 13]

A method of producing a protein in a cell-free protein synthesis system using a template DNA that is produced by the method of any one of claims 1 to 12.

25 [Detailed description of the invention]

[0001]

[Technical field of the invention]

The present invention relates to a method of producing a template DNA for protein synthesis and a method of producing

a protein using a template DNA that is produced by the method.

[0002]

[Related Art]

Regarding a huge number of genes derived from a great
5 deal of genomic sequence information of organisms, a research
called "Structural Genomics" is now in progress, which is a
systematic and comprehensive analysis of the relationship
between structure and function of proteins by determining three
dimensional structures of the proteins encoded by the respective
10 genes. As the total genome sequences were clarified, it was
found that three-dimensional protein structures considered to
be innumerable actually comprise combinations of one to several
thousands of basic structures (folds) and these combinations
seem likely to realize the diversity of functions. Accordingly,
15 high-throughput technologies throughout the processes from
synthesis to structural analysis of proteins will make it
possible to reveal all of the basic structures of the proteins
and based on the knowledge of the basic structures, it will
be enabled to elucidate the relationship between structure and
20 function of the proteins.

[0003]

As a system for expressing and preparing a number of
protein samples at good efficiency, cell-free protein synthesis
systems have been improved by various modifications such as
25 introduction of dialysis, to obtain proteins in the order of
milligrams within several hours (refer to Kigawa et al., FEBS
Lett., vol. 442, pp. 15-19, 1999 and Japanese Patent Kokai
publication JP-A-2000-175695). To express proteins in this
cell-free protein synthesis system at good efficiency, a

double-stranded DNA containing an appropriate expression regulatory region and a gene sequence coding for a target protein to be expressed is needed as a template DNA. In order to express any genes cloned in a cloning vector free of an appropriate expression regulatory sequence in a cell-free protein synthesis system, it is necessary to add an appropriate expression regulatory sequence to these genes. Therefore, several methods have been so far performed, in which a desired DNA fragment is excised from a plasmid vector comprising a gene by restriction enzymes or PCR amplification, then re-cloned in a vector having an appropriate expression regulatory sequence, or a desired DNA fragment was further amplified by PCR.

[0004]

To obtain a highly efficient protein expression, it is required to promote the transcription of the gene with strong promoter or terminator sequence as well as to enhance the translation by improving the affinity between mRNA and ribosomes. Further, for quickly purifying or detecting synthesized proteins, it is also required to design fusion proteins having incorporated therein a tag sequence for affinity purification or detection.

[0005]

[Problems to be solved by Invention]

When the template DNA suitable for such protein synthesis is prepared, however, much expense in time and effort is necessary to clone the DNA by genetic engineering techniques using living cells such as *E. coli*, because the methods are complicated and difficult to make high-throughput by automation. It is also problems to construct the template DNA by complex

recombination, or to synthesize many kinds of primers for PCR for the optimization of respective genes.

[0006]

5 It is therefore an object of the present invention to provide an efficient method of preparing a template DNA to express and purify a protein.

[0007]

[Means to solve the Problems]

10 In view of the foregoing aim, the present inventors have assiduously conducted investigations on a method of producing a template DNA in a cell-free protein synthesis system, and have consequently found that a linear template DNA appropriate for expression of a protein can be synthesized very quickly and efficiently by amplifying an optional cloned DNA selected
15 from cDNA library through 2-step PCR. This finding has led to the completion of the invention.

[0008]

In the first aspect of the present invention, there is provided a method of producing a template DNA used for protein
20 synthesis comprising a step of:

amplifying a linear double-stranded DNA by polymerase chain reaction (PCR), contacting,

a first double-stranded DNA fragment comprising a sequence coding for a protein,

25 a second double-stranded DNA fragment comprising a sequence overlapping with the 5' terminal region of the first DNA fragment,

a third double-stranded DNA fragment comprising a sequence overlapping with the 3' terminal region of the first

DNA fragment,

a sense primer which anneals with the 5' terminal region of the second DNA fragment, and

an anti-sense primer which anneals with the 3' terminal
5 region of the third DNA fragment,

wherein the second DNA fragment comprises a regulatory sequence for transcription and translation of a gene, and the concentrations of the second DNA fragment and the third DNA fragment in the PCR solution each range from 5 to 2,500 pmol/L.

10 [0009]

In a preferred embodiment, the invention is a method to perform the above PCR (the second PCR) after amplifying a DNA by performing a PCR (a first PCR) to prepare the first DNA fragment, using the first PCR solution as the first DNA fragment, the
15 method is characterized in that the respective concentrations of primers remaining in the first PCR solution and primer dimers produced in the first PCR are less than 20 nmol/L in the second PCR solution.

[0010]

20 Thus, the invention is characterized in that for decreasing the amounts, incorporated into the second PCR, of primers used in the first PCR and primer dimers produced as byproducts, the concentrations of the primers used for the first PCR are in the range of from 20 to 500 nmol/L, or the second
25 PCR is performed with the first PCR products which are diluted to 10- to 100-fold (at a final concentration in the second PCR solution), or both of these are performed in combination, or the second PCR is performed after removing the primers and the primer dimers from the first PCR solution.

[0011]

In one embodiment, the invention is characterized in that the first PCR is carried out using recombinant microorganisms or a culture broth thereof comprising the first double-stranded
5 DNA fragment.

[0012]

In another preferred embodiment, the invention is characterized in that the sense primer and the anti-sense primer have the same nucleotide sequence, and/or the second DNA fragment
10 comprises a transcription termination sequence.

[0013]

In the other preferred embodiment, the invention is characterized in that at least one of the second DNA fragment and the third DNA fragment comprises a sequence coding for a
15 tag peptide, and the tag peptide is synthesized by being fused with the protein or a portion thereof. The tag peptide is preferably maltose binding protein, cellulose binding domain, glutathione-S-transferase, thioredoxin, streptavidin binding peptide or histidine tag peptide.

20 [0014]

The invention provides, in another aspect, a method of producing a protein in a cell-free protein synthesis system, characterized by using a template DNA that is produced by any of the foregoing methods.

25 [0015]

[Preferred Embodiments of Invention]

One embodiment of the present invention is described in detail below along the attached drawings. Fig. 1 is a flow chart showing a method of producing a linear double-stranded

template DNA for protein synthesis by 2-step PCR using a plasmid DNA with a full-length cDNA cloned.

[0016]

(1) First PCR

5 With respect to the template DNA of the first PCR, any template DNA will be used, so long as it comprises a sequence coding for a desired protein. For example, not only a DNA cloned from cDNA library but also a genomic DNA clone or a synthetic DNA can be used. Further, an unpurified DNA is also available.

10 For example, a strain carrying a plasmid vector comprising the foregoing sequence or a culture broth of the strain can be used. Fig.1 shows modified bluescript 1 which is a plasmid obtained by cloning mouse full-length cDNA in *Sac*I and *Xho*I sites of plasmid vector pBLUESCRIPT SK+.

15 [0017]

In Fig.1, two primers (5'-primer 1 and 5'-primer 2) are used as 5'-primers for amplifying a protein code region of a cloned cDNA. A nucleotide sequence of the 5'-primer 2 is designed to anneal with a nucleotide sequence corresponding to an amino terminal region of the protein encoded by the cloned cDNA. The 5'-primer 2 can further contain an arbitrary nucleotide sequence in the 5'-terminal side. Meanwhile, the 5'-primer 1 may have a sequence common to a part of the 5'-terminal side of the 5'-primer 2, and both of the primers overlap to function as the 5'-primers of the first PCR.

25 [0018]

On the other hand, in Fig.1, the 3'-primer is designed to anneal with a region of the plasmid vector where is located in the 3' downstream of the protein coding region, and elongates

the DNA chain by PCR together with the 5'-primers to amplify the first DNA fragment coding for the protein to be expressed. Since the first DNA fragment is used as a template of the second PCR to be described later, it can be purified from the PCR reaction solution by a known method, or the PCR reaction solution can also be used directly. In this case, the primers remaining in the reaction solution might inhibit the second PCR reaction. For this reason, it is preferable that the amounts, incorporated into the second PCR solution, of primers used in the first PCR and primer dimers produced as byproducts in the first PCR are decreased to less than 20 nmol/L. Specifically, when plural primers are used as the 5'-primer or the 3'-primer, they are preferably used at a total concentration of from 20 to 500 nmol/L, more preferably from 50 to 100 nmol/L.

15 [0019]

Alternatively, the amounts, incorporated into the second PCR, of the primers and the primer dimers can be reduced by diluting the first PCR solution to 10- to 100-fold.

[0020]

20 Besides such methods, PCR using various primers is possible for obtaining the first DNA fragment. With respect to nucleotide sequences of primers, PCR reaction conditions and the like employed at that time, ordinary ones are available, and it is desirable to properly determine them by those skilled in the art. It is further possible to obtain the first DNA fragment by excising a DNA fragment directly from the cDNA clone with a restriction enzyme or the like.

25 [0021]

(2) Second PCR

Next, the double-stranded second DNA fragment (hereinafter sometimes referred to as "5' DNA fragment") comprising a sequence overlapping with the 5' terminal region of the first DNA fragment is prepared. The second DNA fragment overlaps with the 5' terminal region of the first DNA fragment in its 3' terminal region, whereby these two DNA fragments mutually become primers and a template to allow an elongation reaction, producing a template DNA in the second PCR. The overlapping region is preferably at least 12 base pairs, more preferably at least 17 bases.

[0022]

Subsequently, the double-stranded third DNA fragment (hereinafter sometimes referred to as "3' DNA fragment") comprising a sequence overlapping with the 3' terminal region of the first DNA fragment is produced. The third DNA fragment overlaps with the 3' terminal region of the first DNA fragment in its 5' terminal region, whereby these two DNA fragments mutually become primers and a template to allow an elongation reaction, producing a template DNA in the second PCR. The overlapping region is preferably at least 12 base pairs, more preferably at least 17 bases.

[0023]

Then, as the primers for the second PCR, the sense primer which anneals with the 5' terminal region of the 5' DNA fragment and the anti-sense primer which anneals with the 3' terminal region of the 3' DNA fragment are synthesized. These primers may anneal with the template DNA of the second PCR to allow a DNA elongation reaction and amplify a desired DNA fragment. Plural primers that anneal with the both terminal regions of

the template DNA can be used. Preferably, when the both terminal sequences are complementary nucleotide sequences, an amplification reaction is possible with one type of a primer (universal primer) as shown in Fig.1. This primer usually
5 comprises a single-stranded oligonucleotide of from 5 to 50 bases, preferably a single-stranded oligonucleotide of from 15 to 25 bases. The use of one type of a universal primer is more advantageous than the use of two types of primers because byproducts are less formed by PCR.

10 [0024]

Generally, it is known that byproducts (primer dimers) in which primers are paired are formed by PCR. In case of using two types of primers, primer dimers once formed serve as a template DNA to amplify the byproducts and decrease amounts
15 of primers used for amplification of a desired product. Consequently, an amount of a desired product is considered to be decreased. Meanwhile, when PCR is performed using only one type of a primer, it is considered that the resulting primer dimers tend to take a hairpin structure because they have
20 complementary sequences in the same molecule, and are therefore less amplified by PCR to less form byproducts.

[0025]

The 5' DNA fragment contains sequences of inducing and regulating transcription and translation of a gene in the
25 upstream of the region overlapping with the first DNA fragment. The sequences of inducing and regulating the transcription of the gene are called promoter and operator sequences, and they have been studied in detail in prokaryotic cells and eukaryotic cells such as *Escherichia coli* and yeasts. For example, T7

promoter derived from a phage of *Escherichia coli* is used. It is known that in T7 promoter, potent transcription is performed with T7 RNA polymerase. Translation of an mRNA into a protein is induced by binding a translation initiation complex of a ribosome or the like to an mRNA. A ribosome binding sequence (RBS) is called an SD sequence, and important for efficient expression of a protein.

[0026]

Further, these expression regulatory sequences contain, in the upstream, the sequence with which the sense primer anneals in PCR. The nucleotide sequence of the sense primer here may be one which serves as a primer by being hybridized with the 5' terminal region of the 5' DNA fragment, and it includes one in which one or more bases in the sequence complementary to the template DNA are deleted, substituted or added.

[0027]

Likewise, the 3' DNA fragment contains, in the 3' terminal region, the sequence with which the anti-sense primer anneals in PCR. The anti-sense primer may be one which serves as a primer by being hybridized with the 3' terminal region of the 3' DNA fragment, and it includes one in which one or more bases in the sequence complementary to the template DNA are deleted, substituted or added.

[0028]

The concentrations of the 5' DNA fragment and the 3' DNA fragment in the reaction solution of the second PCR are preferably lower than the concentrations of primer DNAs in usual PCR, and they are used at concentrations of from 5 to 2,500 pmol/L, preferably from 10 to 500 pmol/L. When the

concentrations of these DNA fragments are higher than 2,500 pmol/L, byproducts tend to be formed during PCR. That is, single-stranded DNAs produced from the universal primer bound to the 5' DNA fragment and the 3' DNA fragment are bound in the same manner as the foregoing primer dimers, with the result that byproducts in which the 5' DNA fragment and the 3' DNA fragment are directly bound tend to be formed. The reason is that since these byproducts are shorter than the desired products, they tend to be amplified by PCR, act as a template that expresses only short proteins in the protein synthesis, and have therefore an adverse effect on the protein synthesis.

[0029]

Meanwhile, when the concentrations of the DNA fragments are lower than 5 pmol/L, the amount of a DNA that serves as a template itself is decreased, and a sufficient amount of a desired DNA is not amplified. The other reaction conditions of the second PCR can properly be selected and used by those skilled in the art.

[0030]

It is preferable that the 3' DNA fragment further comprises a transcription termination sequence. The transcription termination sequence is a DNA sequence of prompting separation of an RNA polymerase, and it has generally a characteristic structure of a symmetrical sequence enriched in GC and followed by T to allow an efficient transcription reaction.

[0031]

The second PCR can be performed even with one or both of the 5' DNA fragment and the 3' DNA fragment being single-stranded DNA(s) instead of the double-stranded DNA(s),

and this embodiment is also included in the scope of the invention.

[0032]

(3) Tag peptide

5 It is preferable that at least one of the 5' DNA fragment and the 3' DNA comprises a sequence coding for a tag peptide. The tag peptide is an amino acid sequence added to an N terminal and/or a C terminal of a protein to be expressed, and this is a sequence as a mark in affinity purification or western blotting
10 detection of the protein. Examples thereof include glutathione-S-transferase (GST), maltose binding protein (MBP), thioredoxin (TrxA), cellulose binding domain (CBD), streptavidin binding peptide (for example, Streptag (trademark)) and histidine tag peptide.

15 [0033]

Glutathione-S-transferase (GST) is a soluble enzyme protein. When a desired gene is incorporated in the downstream of this gene sequence by adapting the frame thereto, a fusion protein with GST can be expressed. Recombinant vectors, pGEX
20 Vectors for this purpose are commercially available from Amersham Pharmacia Biotech. It is used for affinity purification or enzymatic immunostaining by utilizing an antibody that specifically recognizes a protein portion of GST or a property of binding to glutathione.

25 [0034]

The maltose binding protein (MBP) is maltose binding protein of *Escherichia coli*. A fusion protein with MBP can be adsorbed on amylose or agarose gel, then separated with excess maltose and purified. Further, anti-MBP antibody can also be

used.

[0035]

Thioredoxin (TrxA) is a protein of *Escherichia coli* that catalyzes a redox reaction, and can be purified by metal chelate affinity chromatography with a pair of functional thiol groups. As a carrier for this purpose, for example, ThioBond (trademark) Resin (manufactured by Invitrogen) is commercially available.

[0036]

The cellulose binding domain (CBD) is a cellulose binding domain sequence derived from *Clostridium cellulovorans* and *Cellulomonas fimi*, and has a property of specifically binding to cellulose. It can be immobilized on an inert carrier such as cellulose or chitin without chemical modification.

[0037]

As the streptavidin binding peptide, for example, a peptide made of 8 amino acids, called Strep-tag II, is known, and it can be purified by being bound selectively to Streptactin (trade mark) or Streptavidine (trademark).

[0038]

As the histidine tag, a peptide comprising at least 6 histidines which are located continuously or in close proximity is preferable. The protein encoded by the first DNA fragment is bound to this histidine tag either directly or through an amino acid sequence. The histidine tag has a high affinity for a divalent metallic atom, especially, a nickel atom. Accordingly, the protein having the histidine tag is firmly bound to a nickel affinity matrix and can easily be purified.

[0039]

In an especially preferable embodiment, the histidine

tag has an amino acid sequence described in SEQ ID No.1. This sequence is a natural sequence (native His tag) derived from an N terminal of a lactic acid hydrogenase of a chicken muscle. Since the 6 histidine residues being basic amino acids are present by being properly separated, this is advantageously lower in isoelectric point than the histidine tag comprising the continuous 6 histidine residues and enables affinity purification under neutral buffer conditions.

[0040]

In this embodiment, these tag peptides are useful for affinity purification or detection of the expressed protein. In addition, the fusion protein with the tag peptide is sometimes increased in expression amount in comparison to natural proteins. The reason is, though not clear, presumably that a complex with an mRNA, ribosome or the like is stabilized at the translation initiation stage to increase translation efficiency.

[0041]

These tag sequences may contain, in the downstream thereof, a nucleotide sequence that can provide a cleavage site of a protease such as thrombin, Factor Xa or enterokinase, and a desired protein can be purified by being separated from the tag sequences.

[0042]

Further, it is also possible that the tag sequences are located on the C terminal side of the desired protein and purification can easily be conducted while a function of a leader sequence of the N terminal side remains.

[0043]

(4) Protein synthesis using a cell-free protein synthesis

system

The thus-produced template DNA can synthesize a protein by various methods. For example, it is preferable that a protein is synthesized in a cell-free protein synthesis system. The cell-free protein synthesis system is a system that synthesizes a protein *in vitro* using a cell extract. As the cell extract, an extract of hitherto-known eukaryotic cells or prokaryotic cells, containing ingredients necessary for protein synthesis, such as ribosome and t-RNA, can be used. A cell extract derived from wheat germ, *Escherichia coli* (for example, *E. coli* S30 cell extract) or *Thermus thermophilus* is preferable because a high synthesis amount is obtained. This *E. coli* S30 cell extract can be produced from *E. coli* A19 (rna met), BL21, BL21 star, BL21 codon plus or the like according to a known method (refer to Pratt. J. M. et al., Transcription and translation - a practical approach, (1984), pp. 179-209, compiled by Henes, B. D. and Higgins, S. J., IRL Press, Oxford), or a product marketed from Promega, Novagen or Roche may be used.

[0044]

Any of a batchwise method, a flow method and other known techniques can be applied to the cell-free protein synthesis system of the invention. Examples thereof can include a ultrafiltration membrane method, a dialysis membrane method, and a column chromatography method in which a translation template is fixed on a resin (refer to Spirin, A. et al., Meth. In Enzymol. vol. 217, pp. 123 - 142, 1993).

[0045]

Besides the cell-free protein synthesis system, it is also possible that, for example, a template DNA is introduced

into animal cells through lipofection or the like to express a gene, and a function of the gene product in viable cells is analyzed.

[0046]

5 [Examples]

In the following Examples of the present invention, the results of expressing, in a cell-free protein synthesis system, human c-Ha-Ras protein, chloramphenicol acetyl transferase (CAT) and various cDNA clones arbitrarily selected from mouse
10 full-length cDNA library (provided from Dr. Hayashizaki Yoshihide, Genome Exploration Research Group, Genomic Sciences Center, RIKEN) are described in detail below. However, the invention is not limited to these Examples.

[0047]

15 [Example 1] Expression of Ras protein

(1) First PCR

PCR was performed using a linear double-stranded DNA (nucleotide sequence was described in SEQ ID No. 2) coding for Ras protein as a template and three types of primers, 5' primer
20 1: hRBS>B+6 (SEQ ID No. 3), 5' primer 2: pRas (SEQ ID No. 4) and 3' primer: p8.2 (SEQ ID No. 5). The composition of the PCR solution and the amplification program were shown in Tables 1 and 2 respectively.

[0048]

25 5' primer 1: hRBS>B+6 (SEQ ID No. 3)

5'-CCGAAGGAGCCGCCACCAT-3'

5' primer 2: pRas (SEQ ID No. 4)

5'-GAAGGAGCCGCCACCATGACCGAATACAAACTGGTTGTAG-3'

3' PRIMER: p8.2 (SEQ ID No. 5)

5' -GCGGATAACAATTTACACAGGAAAC-3'

[0049]

[Table 1]

Composition	Concentration	Amount	Final concentration
Template plasmid	1 ng/μl	4 μl	0.2 ng/μl
5' Primer 1 (hRBS>B+6)	1.6 μM	1 μl	0.08 μM
5' Primer 2	0.2 μM	2 μl	0.02 μM
3' Primer (p8.2)	2 μM	1 μl	0.1 μM
dNTPs (Toyobo)	2 mM	2 μl	0.2 mM
Expand HF buffer (Boehringer Mannheim)	(10 x)	2 μl	(1x)
(containing 15 mM magnesium chloride)			
Sterile distilled water		7.85 μl	
DNA polymerase (Boehringer Mannheim)	3.5 U/μl	0.15 μl	0.02625 U/μl
Total amount		20 μl	

5 [0050]

[Table 2]

STEP 1	94°C	2 min
STEP 2	94°C	30 sec
STEP 3	60°C	30 sec
STEP 4	72°C	2 min
STEP 5	GOTO 2 for 9 times	
STEP 6	94°C	30 sec
STEP 7	60°C	30 sec
STEP 8	72°C	2 min + 5 sec/cycle
STEP 9	GOTO 6 for 19 times	
STEP 10	72°C	7 min
STEP 11	4°C	forever

[0051]

(2) Second PCR

10 Subsequently, the second overlap PCR was performed using the first PCR products obtained in the foregoing reaction, 5' DNA fragment: T7P (one of SEQ ID Nos. 6 to 10) having respective tag sequence in the downstream of the T7 promoter sequence, 3' DNA fragment: T7T (SEQ ID No. 11) having a T7 terminator sequence and universal primer (YA1.2):

15

5'-GCCGCTGTCCTCGTTCCCAGCC-3' (SEQ ID No. 12). The composition of the PCR solution and the amplification program were shown in Tables 3 and 2 respectively. Further, the outline of the tag peptides encoded in the 5' DNA fragment used here was shown in Table 4. Consequently, as shown in Fig.1, a linear double-stranded DNA fragment capable of expressing a fusion protein of various tag sequences and Ras protein was amplified under control of the T7 promoter.

[0052]

10 [Table 3]

Composition	Concentration	Amount	Final concentration
First PCR product (template)	(x 1/5)	5 μ l	(x 1/20)
Universal primer (YA1. 2)	100 μ M	0.2 μ l	1 μ M
5' Fragment (T7P fragment)	2 nM	1 μ l	0.1 nM
3' Fragment (T7T fragment)	2 nM	1 μ l	0.1 nM
dNTPs (Toyobo)	2 mM	2 μ l	0.2 mM
Expand HF buffer (Boehringer Mannheim)	(10 x)	2 μ l	(1x)
(containing 15 mM magnesium chloride)			
Sterile distilled water		8.65 μ l	
DNA polymerase (Boehringer Mannheim)	3.5 U/ μ l	0.15 μ l	0.02625 U/ μ l
Total amount		20 μ l	

[0053]

[Table 4]

1	GST	glutathione-S-transferase
2	MBP	maltose binding protein
3	TrxA	thioredoxin
4	CBD	cellulose binding protein
5	His tag	MKGSSHHHHHH
6	native His tag	MKDHLIHNVHKEEHAHAHNK

15 By the way, with respect to His tag and native His tag, amino acid sequences thereof were shown by one-letter abbreviations.

[0054]

(3) Protein synthesis in a cell-free protein synthesis

system

E. coli S30 extract was prepared from *E. coli* BL21 strain according to a method of Zubay et al. (Annu. Rev. Geneti., 7, 267-287, 1973). With respect to the protein synthesis reaction, Ras protein was synthesized at 37°C for 1 hour using a 96-well microplate by adding 1 µl of the second PCR products and 7.2 µl of the *E. coli* S30 extract to a solution of a composition shown in Table 5 below in each well thereof to adjust the whole volume of the reaction solution to 30 µl.

10 [0055]

[Table 5]

Composition	Concentration
HEPES-KOH pH 7.5	58.0 mM
Dithiothreitol	2.3 mM
ATP	1.2 mM
CTP, GTP, UTP	0.9 mM each
Creatine phosphate	81.0 mM
Creatine kinase	250.0 µg/ml
Polyethylene glycol 8000	4.0%
3',5'-cAMP	0.64 mM
L(-)-5-formyl-5,6,7,8-tetrahydrofolic acid	35.0 µg/ml
<i>E. coli</i> total tRNA	170.0 µg/ml
Potassium glutamate	200.0 mM
Ammonium acetate	27.7 mM
Magnesium acetate	10.7 mM
Amino acids	1.5 mM each
T7 RNA polymerase (Toyobo)	16.0 units/µl

[0056]

[Example 2] Expression of CAT protein

15 (1) First PCR

The first PCR was performed in the same manner as in Example 1 using, as a template, a linear double-stranded DNA having a nucleotide sequence described in SEQ ID No. 13 which DNA codes for CAT protein. In this connection, primer pCAT specific for
20 CAT gene and having a nucleotide sequence described in SEQ ID

No. 14 was used as 5' primer 2.

[0057]

5' primer 2: pCAT (SEQ ID No. 14)

5'-GAAGGAGCCGCCACCATGGAGAAAAAATCACTGGATATAC-3'

5 [0058]

(2) Second PCR and protein synthesis in a cell-free protein synthesis system

The protein was synthesized in a cell-free protein synthesis system after second PCR in the same manner as in Example

10 1.

[0059]

[Example 3] Expression of mouse cDNA clones

(1) First PCR

Ten types of cDNA clones optionally selected from mouse
15 full-length cDNA library were used as a template. These are
obtained by cloning the respective cDNAs in *Sac*I and *Xho*I sites
of plasmid pBluescriptSK+, and have been registered in GenBank
(Accession Nos. are m16206, m21532, x13605, u51204, l16904,
s68022, d87663, x65627, m32599 and u85511 respectively). PCR
20 was performed using the common primers in Example 1 as 5' primer
1 and 3' primer and primers specific for the respective cDNAs
and having the following nucleotide sequences as 5' primer 2.
The composition of the PCR solution and the program were shown
in Tables 6 and 2 respectively.

25 [0060]

5' primer 2: p1A2 (SEQ ID No. 15)

5'-GAAGGAGCCGCCACCATGCTCAAAGTCACGGTGCCC-3'

5' primer 2: p1B2 (SEQ ID No. 16)

5'-GAAGGAGCCGCCACCATGGAGGAGCAGCGCTGTTC-3'

5' primer 2: p1C8 (SEQ ID No. 17)

5'-GAAGGAGCCGCCACCATGGCCCGAACCAAGCAGAC-3'

5' primer 2: p1D2 (SEQ ID No. 18)

5'-GAAGGAGCCGCCACCATGGGTGTTGACAAAATCATTC-3'

5 5' primer 2: p1D9 (SEQ ID No. 19)

5'-GAAGGAGCCGCCACCATGTTGGAGACCTACAGCAACC-3'

5' primer 2: P1d10 (SEQ ID No. 20)

5'-GAAGGAGCCGCCACCATGGCGGTGCAGGTGGTGC-3'

5' primer 2: p1E4 (SEQ ID No. 21)

10 5'-GAAGGAGCCGCCACCATGGATGATCGGGAGGATCTG-3'

5' primer 2: P1G4 (SEQ ID No. 22)

5'-GAAGGAGCCGCCACCATGTCGAGTTATTCTAGTGAC-3'

5' primer 2: p1H1 (SEQ ID No. 23)

5'-GAAGGAGCCGCCACCATGGTGAAGGTCGGTGTGAAC-3'

15 5' primer 2: p1H5 (SEQ ID No. 24)

5'-GAAGGAGCCGCCACCATGGCCAACAGTGAGCG-3'

[0061]

[Table 6]

Composition	Concentration	Amount	Final concentration
Template plasmid	0.2 ng/ μ l	4 μ l	0.04 ng/ μ l
5' Primer 1 (hRBS>B+6)	10 μ M	1 μ l	0.5 μ M
5' Primer 2	0.1 μ M	1 μ l	0.005 μ M
3' Primer (p8.2)	10 μ M	1 μ l	0.5 μ M
dNTPs (Toyobo)	2 mM	2 μ l	0.2 mM
Expand HF buffer (Boehringer Mannheim) (containing 15 mM magnesium chloride)	(10 x)	2 μ l	(1x)
Sterile distilled water		8.85 μ l	
DNA polymerase (Boehringer Mannheim)	3.5 U/ μ l	0.15 μ l	0.02625 U/ μ l
Total amount		20 μ l	

20 [0062]

(2) Second PCR

Second PCR was performed in the same manner as in Example

1. However, regarding the composition of the PCR solution, a reaction solution of a composition shown in Table 7 was used instead of that shown in Table 3.

[0063]

5 [Table 7]

Composition	Concentration	Amount	Final concentration
First PCR product (template)	(x 1/10)	5 μ l	(x 1/40)
Universal primer (YA1. 2)	100 μ M	0.2 μ l	1 μ M
5' Fragment (T7P fragment)	2 nM	0.5 μ l	0.05 nM
3' Fragment (T7T fragment)	2 nM	0.5 μ l	0.05 nM
dNTPs (Toyobo)	2 mM	2 μ l	0.2 mM
Expand HF buffer (Boehringer Mannheim)	(10 x)	2 μ l	(1x)
(containing 15 mM magnesium chloride)			
Sterile distilled water		9.65 μ l	
DNA polymerase (Boehringer Mannheim)	3.5 U/ μ l	0.15 μ l	0.02625 U/ μ l
Total amount		20 μ l	

[0064]

[Example 4] Confirmation of synthetic products

The results of analyzing by agarose gel electrophoresis a part of the reaction solutions amplified by PCR according to the methods of Examples 1 and 2 were shown in Fig. 2. Lanes 1 to 7 show the following respectively. 1: first PCR products, 2: second PCR products with the addition of His tag, 3: second PCR products with the addition of native His tag, 4: second PCR products with the addition of GST tag, 5: second PCR products with the addition of MBP tag, 6: second PCR products with the addition of CBD tag, and 7: second PCR products with the addition of TrxA tag. It is found that only a single DNA band is detected in both the first PCR and the second PCR and DNAs of correct lengths having bound thereto tag sequences coding for the respective tag peptides are amplified in the second PCR.

[0065]

The proteins synthesized in the cell-free synthesis system by the methods of Examples 1 and 2 were quantitatively determined using TOPCOUNT after synthesis in the presence of ^{14}C labeled Leu. The results were shown in Table 8 below and Fig. 3. Table 8 showed a presumptive molecular weight and an expression amount of Ras protein and CAT protein synthesized as fusion proteins with 6 types of tag peptides. Results of synthesis without the addition of a DNA and results of synthesis in a cell-free protein synthesis system using plasmids pk7-Ras and pk7-CAT (refer to Kigawa et al., FEBS Lett., vol. 442, pp. 15-19, 1999) which are circular double-stranded DNAs were shown as a control. These results revealed that the expression amounts were approximately the same as those in using as a template the circular double-stranded DNA without these tag peptides, though they vary with the types of the tag peptides used.

[0066]

[Table 8]

Tag sequence	Ras		CAT	
	Molecular weight (kDa)	Expression amount ($\mu\text{g/ml}$)	Molecular weight (kDa)	Expression amount ($\mu\text{g/ml}$)
His tag	22.2	45.3	28.4	99.1
Native His	20.7	268.9	29.5	413.7
GST	42.6	293.8	52.8	374.9
MBP	57.3	663.1	67.4	684.8
CBD	37.8	467.8	44.0	493.9
TrxA	28.7	375.2	38.9	335.8
No addition of DNA	-	14.1	-	-
pk7-Ras	-	498.5	-	-
pk7-CAT	-	-	28.6	478.4

20 [0067]

Further, the results obtained by performing SDS-PAGE using 5 μl of the solution resulting from the protein synthesis

in the presence of ^{14}C -labeled Leu were shown in Fig. 4. In Fig. 4, lanes 1 to 7 show the following respectively. 1: Ras or CAT protein with the addition of His tag, 2: Ras or CAT protein with the addition of native His tag, 3: Ras or CAT protein with GST tag, 4: Ras or CAT protein with the addition of MBP tag, 5: Ras or CAT protein with the addition of CBD tag, and 6: Ras or CAT protein with the addition of TrxA tag. In the drawing, in lanes indicated as Ras and CAT, proteins synthesized in a cell-free protein synthesis system using plasmids pk7-Ras and pk7-CAT as a template are shown as a control, and H and L indicate a high-molecular-weight marker and a low-molecular-weight marker respectively. From these results, it is found that Ras and CAT proteins with the addition of the respective tags are synthesized with correct molecular weights.

15 [0068]

Synthesis amounts of proteins derived from mouse cDNA clones synthesized by fusion with GST and native His tag sequences according to the method in Example 3 were shown in Fig. 5. These results revealed that proteins can be synthesized efficiently from cDNA clones of many samples.

20 [0069]

[Comparative Example 1]

Two-step PCR was performed in the same manner as in Examples 1 and 2 by varying concentrations of the 5' DNA fragment (T7P (GST) or T7P (His tag)) and the 3' DNA fragment (T7T) used in the second PCR. All of the other conditions were the same as in Examples 1 and 2. The results of examining the second PCR products by 1% agarose gel electrophoresis were shown in Table 9.

[0070]

[Table 9]

Sample	1	2	3	4	5	6	7
Concentrations of T7P and T7T in second PCR solution (pmol/L)	1	5	50	500	2500	5000	10000
Results of analysis by agarose gel electrophoresis							
Ras + GST tag	-	-	O	O	Δ	Δ	Δ
Ras + His tag	-	O	O	O	O	Δ	Δ
CAT + GST tag	-	O	O	O	Δ	Δ	Δ
CAT + His tag	-	O	O	O	O	Δ	Δ
no DNA + GST tag	-	-	-	-	x	x	x
no DNA + His tag	-	-	-	x	x	x	x

[0071]

5 The criteria of the agarose gel electrophoresis are as follows.

-: No PCR product

O: Only correct PCR products are confirmed.

Δ: Both correct PCR products and byproducts are confirmed.

10 x: Only byproducts are confirmed.

[0072]

From these results, it is clear that when the respective concentrations of the 5' DNA fragment and the 3' DNA fragment in the second PCR solution are 1 pmol/L, the DNA amplification does not occur, while when the concentrations are 5,000 pmol/L or more, the amounts of byproducts are increased to decrease the purity of the template DNA. Accordingly, it is found that when the respective concentrations of the 5' DNA fragment and the 3' DNA fragment are within the range of from 5 to 2,500 pmol/L, the amplification of the template DNA occurs efficiently.

[0073]

[Comparative Example 2]

Two-step PCR was performed in the same manner as in Examples 1 and 2 by varying concentrations of primers used in the first PCR as follows. T7P (GST) and T7P (His tag) were used as the 5' DNA fragment in the second PCR. All of the other conditions were the same as in Examples 1 and 2. The results of examining the second PCR products by 1% agarose gel electrophoresis were shown in Table 10.

[0074]

[Table 10]

Sample	1	2	3	4	5	6	7
Concentration of primer in first PCR solution (nmol/L)							
hRBS>B+6 primer	5	15	40	80	230	480	980
pRas or pCAT	5	10	10	20	20	20	20
p8. 2 primer	10	25	50	100	250	500	1000
Concentration of primer in second PCR solution (nmol/L)							
p8. 2 primer	0.5	1.25	2.5	5	12.5	25	50
Results of analysis by agarose gel electrophoresis							
Ras + GST tag	-	-	O	O	O	x	x
Ras + His tag	-	O	O	O	O	Δ	Δ
CAT + GST tag	-	O	O	O	O	x	x
CAT + His tag	-	O	O	O	O	O	Δ
no DNA + GST tag	-	-	-	-	x	x	x
no DNA + His tag	-	-	-	-	x	x	x

10

[0075]

The criteria of the agarose gel electrophoresis are as follows.

-: No PCR product

15

O: Only correct PCR products are confirmed.

Δ: Both correct PCR products and byproducts are confirmed.

x: Only byproducts are confirmed.

[0076]

From these results, it is clear that in the production of the template DNA for expression of Ras and CAT, the amounts

20

of byproducts are increased when the concentration of 3' primer:
p8.2 used in the first PCR as an index is 25 nmol/L or more
and the amplification of the desired DNA is therefore not
conducted. Even when the template DNA was not used as a control,
5 the amplification of only byproducts corresponding to primer
dimers was confirmed. Meanwhile, when the concentration of
the primer used in the first PCR was 10 nmol/L or less, no efficient
DNA amplification was confirmed in the second PCR.

[0077]

10 [Effects of the Invention]

According to the method of the present invention, the
template DNA for synthesis, purification and detection of the
protein in the cell-free protein synthesis system or the like
can be produced rapidly and efficiently on the basis of the
15 cDNA or genomic DNA comprising the sequence coding for the
protein. This enables construction of an automated system for
the structure and functional analysis of the protein used for
study of the Structural Genomics.

[0078]

20 [Sequence Listing]

SEQUENCE LISTING

25 <110> RIKEN

<120> Methods for producing a linear template DNA and producing a protein
30 in cell free system using thereof

<130> RJH13-021T

5 <160> 24

10 <170> PatentIn version 3.1

<210> 1

15 <211> 20

<212> PRT

20 <213> Artificial Sequence

<220>

25 <223> native His tag

<400> 1

30 Met Lys Asp His Leu Ile His Asn Val His Lys Glu Glu His Ala His
1 5 10 15

35 Ala His Asn Lys
20

<210> 2

40 <211> 605

<212> DNA

<213> Artificial Sequence

5 <220>

<223> double stranded linear DNA coding for Ras protein

<400> 2

10	ggcgtataca tatgaccgaa tacaaactgg ttgtagttgg cgctgggtgg gtaggcaaaa	60
	gcgcgctgac caticagttg atccagaacc acttcgtaga tgagtacgac cgcactattg	120
	aagactctta ccgtaagcag gttgttatcg acggtgagac ctgtttgctg gacatccttg	180
	ataccgcagg ccaagaagaa tactctgcta tgcgtgatca gtatatgctg accggcgaag	240
	gcttctgtg cgttttcgct atcaacaaca ccaaattctt tgaagacatc catcaatacc	300
15	gtgaacagat caaacgtgtt aaagactctg atgacgttcc gatggttctg gttggttaaca	360
	aatgcgactt ggcagcgcgt actgttgaat ctgcgcaggc tcaggatctg gctcgttctt	420
	acggaattcc gtacatcgaa acctctgcta aaactcgtca aggcgttgaa gacgctttct	480
	acaccttggt tcgtgaaatc cgtcagcaca agctgcgtaa gctttgatag aattccgtga	540
	tagctcgagt cgaccggctg ctaacaaagc ccgaaagggt ttctgtgtg aaattgttat	600
20	ccgct	605

<210> 3

<211> 19

25

<212> DNA

<213> Artificial Sequence

30

<220>

<223> 5' primer-1 universal

35

<400> 3

ccgaaggagc cgccaccat

19

<210> 4

40

<211> 40

<212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> 5' primer-2 for Ras
 10 <400> 4
 gaaggagccg ccaccatgac cgaatacaaa ctggtttag 40
 <210> 5
 15 <211> 26
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 25 <223> 3' primer universal
 <400> 5
 gcggataaca atttcacaca ggaaac 26
 30 <210> 6
 <211> 844
 35 <212> DNA
 <213> Artificial Sequence
 40 <220>

<223> 5' DNA fragment comprising GST tag sequence

<400> 6

	ccgctgtcct cgttcccagc ccatgattac gaattcagat ctcgatcccg cgaaattaat	60
5	acgactcact atagggagac cacaacggtt tccctctaga aataattttg tttaacttta	120
	agaaggagat atacatatgt cccctatact aggttattgg aaaattaagg gccttgtgca	180
	accactcga cttcttttgg aatatcttga agaaaaatat gaagagcatt tgtatgagcg	240
	cgatgaagg gataaatggc gaaacaaaaa gtttgaattg ggtttggagt ttcccaatct	300
	tccttattat attgatggtg atgttaaatt aacacagtct atggccatca tacgttatat	360
10	agctgacaag cacaacatgt tgggtggttg tccaaaagag cgtgcagaga tttcaatgct	420
	tgaaggagcg gttttggata ttagatacgg tgtttcgaga attgcatata gtaaagactt	480
	tgaactctc aaagttgatt ttcttagcaa gctacctgaa atgctgaaaa tgttcgaaga	540
	tcgtttatgt cataaaacat atttaaattg tgatcatgta acccatcctg acttcatgtt	600
	gtatgacgct ctgatgttg ttttatacat ggaccaatg tgcttgatg cgttcccaaa	660
15	attagtttgt tttaaaaaac gtattgaagc tateccacaa attgataagt acttgaaatc	720
	cagcaagtat atagcatggc ctttgcaggg ctggcaagcc acgtttggtg gtggcgacca	780
	tcctccaaaa tcggaatagc ctggcgccct cctggtgcc cgcggatccg aaggagccgc	840
	cacc	844

20 <210> 7

<211> 217

<212> DNA

25

<213> Artificial Sequence

30 <220>

<223> 5' DNA fragment comprising His tag sequence

<400> 7

35	ccgctgtcct cgttcccagc ccatgattac gaattcagat ctcgatcccg cgaaattaat	60
	acgactcact atagggagac cacaacggtt tccctctaga aataattttg tttaacttta	120
	agaaggagat atacatatga aaggcagcag ccatcatcat catcatcaca gcagcggcgc	180
	ctccctgggtg ccacgcggat ccgaaggagc cgccacc	217

40 <210> 8

<211> 244

<212> DNA

<213> Artificial Sequence

5

<220>

10 <223> 5' DNA fragment comprising native His tag sequence

<400> 8

	ccgctgtcct cgttcccagc ccatgattac gaattcagat ctcgatcccg cgaaattaat	60
	acgactcact atagggagac cacaacggtt tccctctaga aataattttg ttttaacttta	120
15	agaaggagat atacatatga aagatcatct catccacaat gtccacaaag aggagcacgc	180
	tcatgcccac aacaagagct ctggcgcctc cctggtgcca cgcggatccg aaggagccgc	240
	cacc	244

<210> 9

20

<211> 652

<212> DNA

25 <213> Artificial Sequence

<220>

30

<223> 5' DNA fragment comprising CBD

<400> 9

	ccgctgtcct cgttcccagc ccatgattac gaattcagat ctcgatcccg cgaaattaat	60
35	acgactcact atagggagac cacaacggtt tccctctaga aataattttg ttttaacttta	120
	agaaggagat atacatatgt cagttgaatt ttacaactct aacaaatcag cacaacaaa	180
	ctcaattaca ccaataatca aaattactaa cacatctgac agtgatttaa atttaaataa	240
	cgtaaaagtt agatattatt acacaagtga tggtagacaa ggacaaactt tctggtgtga	300
	ccatgctggg gcattattag gaaatagcta tgttgataac actagcaaag tgacagcaaa	360
40	cttcgtttaa gaaacagcaa gcccaacatc aacctatgat acatatgttg aatttggatt	420
	tgcaagcgga gcagctactc ttaaaaaagg acaatttata actattcaag gaagaataac	480
	aaaatcagac tgggtcaaact acactcaaac aaatgactat tcatttgatg caagtagttc	540

aacaccagtt gtaaataccaa aagttacagg atatataggt ggagctaaag ttcttggtac 600
 agcaagctct ggcgcctccc tggtgccacg cggatccgaa ggagccgcca cc 652

5 <210> 10
 <211> 511
 <212> DNA

10 <213> Artificial Sequence

15 <220>
 <223> 5' DNA fragment comprising Thioredoxin sequence

20 <400> 10
 ccgctgtcct cgttcccagc ccatgattac gaattcagat ctcgatcccg cgaaattaat 60
 acgactcact ataggagac cacaacggtt tccctctaga aataatttg tttaacttta 120
 agaaggagat atacatatga gcgataaaat tattcacctg actgacgaca gttttgacac 180
 ggatgtactc aaagcggacg gggcgatcct cgtcgatttc tgggcagagt ggtgcggtcc 240
 gtgcaaaatg atcgccccga ttctggatga aatcgctgac gaatatcagg gcaaactgac 300
 cgttgcaaaa ctgaacatcg atcaaaaccc tggcactgcg ccgaaatatg gcatccgtgg 360
 25 tatcccgact ctgctgctgt tcaaaaacgg tgaagtggcg gcaaccaaag tgggtgact 420
 gtctaaaggt cagttgaaag agttcctcga cgctaacctg gccagctctg gcgcctccct 480
 ggtgccacgc ggatccgaag gagccgccac c 511

30 <210> 11
 <211> 183
 <212> DNA

35 <213> Artificial Sequence

40 <220>
 <223> 3' DNA fragment comprising T7 terminator

<400> 11
 gtttcctgtg tgaaattggt atccgctgct gagttggctg ctgccaccgc tgagcaataa 60
 ctagcataac cccttggggc ctctaaacgg gtcttgaggg gttttttgct gaaaggagga 120
 actatatccg gataacctcg agctgcaggc atgcaagcgt ggggctggga acgaggacag 180
 5 cgg 183

<210> 12
 <211> 22
 10 <212> DNA
 <213> Artificial Sequence

15
 <220>
 <223> universal primer for 2nd PCR
 20 <400> 12
 gccgctgtcc tcgttcccag cc 22

25 <210> 13
 <211> 760
 <212> DNA
 30 <213> Artificial Sequence

35 <220>
 <223> double stranded linear DNA coding for CAT protein

40 <400> 13
 ggcgtataca tatggagaaa aaaatcactg gatataccac cgttgatata tcccaatggc 60
 atcgtaaaga acattttgag gcatttcagt cagttgctca atgtacctat aaccagaccg 120
 ttcagctgga tattacggcc tttttaaaga ccgtaaagaa aaataagcac aagttttatc 180
 cggcctttat tcacattctt gccgcctga tgaatgctca tccggaattc cgtatggcaa 240

	tgaaagacgg tgagctgggtg atatgggata gtgttcaccc ttgttacacc gttttccatg	300
	agcaaactga aacgttttca tcgctctgga gtgaatacca cgacgatttc cggcagtttc	360
	tacacatata ttcgcaagat gtggcgtgtt acggtgaaaa cctggcctat ttccctaaag	420
	ggtttattga gaatatgttt ttctgtctcag ccaatccctg ggtgagtttc accagttttg	480
5	atttaaactg ggccaatatg gacaacttct tcgccccgt tttcaccatg ggcaaatatt	540
	atacgcaagg cgacaagggtg ctgatgccgc tggcgattca ggttcatcat gccgtctgtg	600
	atggcttcca tgtcggcaga atgcttaatg aattacaaca gtactgcgat gagtggcagg	660
	gcggggcgta attttttttaa ggcagttatt ggtgccctta aacgtcgacc ggctgctaac	720
	aaagcccgaagggtttcct gtgtgaaatt gttatccgct	760
10	<210> 14	
	<211> 41	
15	<212> DNA	
	<213> Artificial Sequence	
20	<220>	
	<223> 5' primer-2 for CAT	
25	<400> 14	
	gaaggagccg ccaccatgga gaaaaaaatc actggatata c	41
	<210> 15	
30	<211> 36	
	<212> DNA	
	<213> Artificial Sequence	
35	<220>	
40	<223> 5' primer-2 for 1A2	
	<400> 15	

	gaaggagccg ccaccatgct caaagtcacg gtgccc	36
	<210> 16	
5	<211> 35	
	<212> DNA	
	<213> Artificial Sequence	
10		
	<220>	
15	<223> 5' primer-2 for 1B2	
	<400> 16	
	gaaggagccg ccaccatgga ggagcagcgc tgttc	35
20	<210> 17	
	<211> 35	
	<212> DNA	
25	<213> Artificial Sequence	
30	<220>	
	<223> 5' primer-2 for 1C8	
	<400> 17	
35	gaaggagccg ccaccatggc ccgaaccaag cagac	35
	<210> 18	
	<211> 38	
40	<212> DNA	

<213> Artificial Sequence

5 <220>

<223> 5' primer-2 for 1D2

<400> 18

10 gaaggagccg ccaccatggg tgttgacaaa atcattcc

38

<210> 19

<211> 37

15

<212> DNA

<213> Artificial Sequence

20

<220>

<223> 5' primer-2 for 1D9

25

<400> 19

gaaggagccg ccaccatggt ggagacctac agcaacc

37

<210> 20

30

<211> 34

<212> DNA

35 <213> Artificial Sequence

<220>

40

<223> 5' primer-2 for 1D10

	<400> 20	
	gaaggagccg ccaccatggc ggtgcaggtg gtgc	34
	<210> 21	
5	<211> 36	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
15	<223> 5' primer-2 for 1E4	
	<400> 21	
	gaaggagccg ccaccatgga tgatcgggag gatctg	36
20	<210> 22	
	<211> 36	
25	<212> DNA	
	<213> Artificial Sequence	
30	<220>	
	<223> 5' primer-2 for 1G4	
35	<400> 22	
	gaaggagccg ccaccatgtc gagttattct agtgac	36
	<210> 23	
40	<211> 36	
	<212> DNA	

<213> Artificial Sequence

5

<220>

<223> 5' primer-2 for 1H1

10

<400> 23

gaaggagccg ccaccatggt gaaggtcggt gtgaac

36

<210> 24

15

<211> 32

<212> DNA

<213> Artificial Sequence

20

<220>

25

<223> 5' primer-2 for 1H5

<400> 24

gaaggagccg ccaccatggc caacagtgag cg

32

30

[Brief Description of the Drawings]

[Fig.1]

A flow chart shows a method of producing a linear template DNA, which is one embodiment of the present invention.

[Fig.2]

35

A photograph analyzed by agarose gel electrophoresis of samples obtained by PCR amplification of template DNAs coding for Ras and CAT proteins fused with various tag peptides

according to the method of the invention is shown.

[Fig.3]

A graph shows synthesized amounts of Ras and CAT proteins fused with various tag peptides.


5 [Fig.4]

A photograph analyzed by SDS-PAGE of Ras and CAT proteins fused with various tag peptides is shown.


[Fig.5]

10 A graph shows synthesized amounts of proteins derived from mouse cDNA clones synthesized by fusion with GST and native His tag sequences.

[Fig. 1]




[Fig. 2]




Tags

- | | |
|--------------------|-------------------|
| 1: 1st PCR product | |
| 2: His tag | |
| 3: native His | |
| 4: GST | } 2nd PCR product |
| 5: MBP | |
| 6: CBD | |
| 7: TrxA | |


[Fig. 3]



[Fig. 4]



[Fig. 5]



[Name of the Document] Abstract

[Abstract]

[Objects]

To provide a method of efficient production of a template
5 DNA for expression and purification of a protein.

[Means to solve the Problems]

Provided is a method of producing a template DNA used
for protein synthesis comprising a step of amplifying a linear
double-stranded DNA by polymerase chain reaction (PCR), by
10 contacting a first double-stranded DNA fragment comprising a
sequence coding for a protein or a portion thereof, a second
double-stranded DNA fragment comprising a sequence overlapping
with the 5' terminal region of the first DNA fragment, a third
double-stranded DNA fragment comprising a sequence overlapping
15 with the 3' terminal region of the first DNA fragment, a sense
primer which anneals with the 5' terminal region of the second
DNA fragment, and an anti-sense primer which anneals with the
3' terminal region of the third DNA fragment, wherein the second
DNA fragment comprises a regulatory sequence for transcription
20 and translation of a gene, and the concentrations of the second
DNA fragment and the third DNA fragment in the reaction solution
each range from 5 to 2,500 pmol/L.

[Selected Drawing]

Fig.1

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.